title: Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver.
abstract: Although adenovirus is an attractive vehicle for transferring therapeutic genes in vivo, animal studies have indicated that the clinical usefulness of adenoviruses may be limited by their immunogenicity. Although immunosuppressive strategies around the time of initial exposure of adenoviruses have been shown to prevent the formation of neutralizing antibodies and permit the successful readministration of adenoviruses in animals, the practicality of the approaches remains questionable. Because the majority of prospective gene therapy patients have already been infected with wild-type adenoviruses, initial treatment with adenoviruses in humans may correspond to readministration of adenoviruses into animals. It is shown here that although intraportal infusion of adenoviruses carrying a reporter lacZ gene resulted in transient high levels of transgene expression in the rat liver, intraportal readministration of adenoviruses failed to induce detectable levels of transgene expression. Conversely, when animals were treated transiently with cyclophosphamide before the intraportal readministration of adenoviruses, development of neutralizing antibodies and antigen-specific T cell proliferation in response to adenoviral readministration was significantly suppressed and successful re-expression of the transgene was achievable. These results may have important implications for efficacy considerations when adenoviral vectors are employed in clinical settings.
authors.affiliation: Third Department of Internal Medicine, Nara Medical University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kuriyama
authors.forename: K
authors.initials: K
authors.lastname: Tominaga
authors.forename: M
authors.initials: M
authors.lastname: Kikukawa
authors.forename: T
authors.initials: T
authors.lastname: Tsujimoto
authors.forename: T
authors.initials: T
authors.lastname: Nakatani
authors.forename: H
authors.initials: H
authors.lastname: Tsujinoue
authors.forename: H
authors.initials: H
authors.lastname: Okuda
authors.forename: S
authors.initials: S
authors.lastname: Nagao
authors.forename: A
authors.initials: A
authors.lastname: Mitoro
authors.forename: H
authors.initials: H
authors.lastname: Yoshiji
authors.forename: H
authors.initials: H
authors.lastname: Fukui
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D000818:Animals; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007763:Lac Operon; D008099:Liver / Q000276:immunology*; D011169:Portal Vein; D051381:Rats; D017207:Rats, Sprague-Dawley; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide